ESElmo Saarentaus

Elmo Saarentaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elmo Saarentaus has a total of 283 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GWAS of Second‐Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways

    by M. Niemi, S. Ruotsalainen, E. Saarentaus, I. Vähätalo, F. FinnGen, I. Starskaia, T. Harju, M. Pelkonen, T. Feuth, P. Kauppi, et al.

    Summary: Four of 67 loci were specific to antihistamine use; most overlapped inflammatory disease susceptibility. Genetic variation enriched in IL‐2 cytokine, JAK–STAT pathway genes shared by allergy and autoimmunity.

  • Open Access

    GWAS of Second-Generation Antihistamine Use: Locus Specificity and Highlighted Signaling Pathways

    by Niemi M, Ruotsalainen S, Elmo Saarentaus, Vähätalo, Finn Gen, Inna Starskaia, Harju T, Pelkonen M, Thijs Feuth, Paula Kauppi, et al.

    Background Second-generation H 1 -antagonists are widely used to treat multiple allergic and non-allergic chronic conditions. Aims We aimed to identify genetic loci, locus specificity, and enriched signaling pathways associated with long-term systemic second-generation antihistamine (sgAH) use in the context of underlying diseases. Materials and Methods In FinnGen, 38,645 individuals with ≥10 sgAH purchases from Finnish pharmacies were identified, while 201,334 individuals with no such purchases served as controls. Comprehensive drug purchase records and clinical diagnoses were retrieved from national registries. Genome-wide association analysis (GWAS) of sgAH use was conducted using Regenie (17 million genotyped and imputed variants). MAGMA was employed for gene and pathway-level enrichment analysis, and phenotypic specificity of associations was evaluated using MetABF. Results In GWAS for sgAH use, we identified 67 independent loci at genome wide significance (P-8 ). Four of identified loci (near DELEC1/TNFSF8, POU2AF1, RNY1P8/KLF5, and LINC00334/POFUT2 ) were specific for sgAH use. The remaining loci also demonstrated genome-wide significant associations with conditions such as asthma, chronic rhinitis, conjunctivitis, atopic eczema, sinusitis, and urticaria, all of which are indicative of sgAH use. Missense variants were observed in IL6RA , IL4RA , TESPA1 , C17orf58, and one lost-of-function mutation in FLG . The TESPA1 variant lies in a conserved region, suggesting potential structural impact. MAGMA analysis revealed significant associations with four gene sets, including IL-2 family cytokines (P=5.0×10 -9 ). Conclusions Most loci associated with sgAH use overlap with those implicated in the underlying, immune mediated diseases. Independent of diagnosis, IL-2 family cytokines signaling via the common γ-chain and the JAK–STAT pathway is significantly enriched among long-term sgAH users.

  • Open Access

    131 genetic loci highlight immunological pathways and tissues in nasal polyposis and asthma

    by Elmo C. Saarentaus, Kasper Fischer-Rasmussen, Eeva Sliz, Argyro Bizaki-Vallaskangas, Finn Gen, Sanna Toppila-Salmi, Hannu Kankaanranta, Johannes Kettunen, Aarno Palotie, Tarja Laitinen, et al.

    The coexistence of asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with allergic phenotypes, disease severity and failure of first-line treatment for both asthma and CRSwNP. Recent studies have highlighted shared genetic components for these diseases. To better understand this shared component, we perform genome-wide meta-analyses of asthma (n = 71,481), CRSwNP (n = 9626) and chronic rhinosinusitis without nasal polyposis (CRSsNP, n = 15,448) in FinnGen and UKB (685,602 controls). We detect 131 genomic associations, including 17 novel loci for asthma, 33 novel loci for CRSwNP, and one for CRSsNP. A shared impact on asthma and CRSwNP is observed at 71 loci. A cross-trait meta-analysis using all disorders further implicates 17 loci associated with asthma or asthma and CRSwNP. We also find 17 nonsynonymous associating variants, including a novel TP63 missense variant association with CRSwNP (OR = 1.519 [1.331–1.734]). Gene set analyses confirm enrichment of genes involved with type 2 inflammation, Jak-STAT signaling, and FOXP3 signaling. Our results highlight new shared and separate genetic pathways for CRSwNP and asthma. These provide several avenues of further investigation in functional and epidemiological follow-up, and evidence for immunological and non-immunological mechanisms behind both diseases.


  • Open Access

    Novel Genetic Risk Variants Associated with Oral Tongue Squamous Cell Carcinoma

    by Rayan Nikkilä, Antti Mäkitie, Heikki Joensuu, Saara Markkanen, Klaus Elenius, Outi Monni, Aarno Palotie, Elmo Saarentaus, Finn Gen, Tuula Salo, et al.

    Purpose: Limited data from genome-wide association studies (GWAS) focusing on oral tongue squamous cell carcinoma (OTSCC) are available. The present study was conducted to explore genetic associations for OTSCC. Methods: A GWAS on 376 cases of OTSCC was conducted using the FinnGen Data Freeze-12 dataset. The case-cohort included 205 males and 171 females. Cases with malignancies involving the base of the tongue or lingual tonsil were excluded from the case-cohort. Individuals with no recorded history of malignancy were used as controls (n = 407,067). A Phenome-wide association study (PheWAS) was performed for the lead variants to assess their co-associations with other cancers. Results: GWAS analysis identified three genome-wide significant loci associated with OTSCC ( p < 5 × 10–8), located at 5p15.33 (rs27067 near gene LINC01511), 10q24 (rs1007771191 near RPS3AP36), and 20p12.3 (rs1438070080 near PLCB1), respectively. PheWAS showed associations of rs27067 mainly with prostate cancer (OR = 1.06, p = 5.41 × 10 –7 ), and seborrheic keratosis (OR = 1.11, p = 1.51 × 10 –11 ). A co-directional effect with melanoma was also observed (OR = 0.93, p = 6.24 × 10 –5 ). Conclusion: The GWAS detected two novel genetic associations with OTSCC. Further research is needed to identify the genes at these loci that contribute to the molecular pathogenesis of OTSCC.


  • Open Access

    131 genetic loci highlight immunological pathways and tissues in nasal polyposis and asthma

    by Elmo Saarentaus, Kasper Fischer-Rasmussen, Eeva Sliz, Argyro Bizaki-Vallaskangas, Tarja Laitinen, Sanna Toppila-Salmi, Hannu Kankaanranta, Johannes Kettunen, Klaus Bønnelykke, Aarno Palotie, et al.

    The coexistence of asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with allergic phenotypes, disease severity and failure of first-line treatment for both asthma and CRSwNP. Recent studies have highlighted shared genetic components for these diseases. To better understand this shared component, we performed genome-wide meta-analyses of asthma (n = 71,481), CRSwNP (n = 9626) and chronic rhinosinusitis without nasal polyposis (CRSsNP, n = 15,448) in FinnGen and UKB (685,602 controls). We detected 131 genomic associations, including 17 novel loci for asthma, 33 novel loci for CRSwNP, and one for CRSsNP. A shared impact on asthma and CRSwNP was observed at 71 loci. A cross-trait meta-analysis using all disorders further implicated 17 loci associated with asthma or asthma and CRSwNP. These loci largely cluster into three groups, with a shared risk being the most frequent. We also found 17 nonsynonymous associating variants, including a novel TP63 missense variant linked with CRSwNP (OR = 1.519 [1.331–1.734]). Gene set analyses confirmed enrichment of type 2 inflammation genes, and linked FOXP3 signaling to CRSwNP. Our results highlight new shared and separate genetic pathways for CRSwNP and asthma. These provide several avenues of further investigation in functional and epidemiological follow-up, and evidence for immunological and non-immunological mechanisms behind both diseases.

  • Open Access

    Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases

    by Tuomo Kiiskinen, Pyry Helkkula, Kristi Krebs, Juha Karjalainen, Elmo Saarentaus, Nina Mars, Arto Lehisto, Wei Zhou, Mattia Cordioli, Sakari Jukarainen, et al.

    Little is known about the genetic determinants of medication use in preventing cardiometabolic diseases. Using the Finnish nationwide drug purchase registry with follow-up since 1995, we performed genome-wide association analyses of longitudinal patterns of medication use in hyperlipidemia, hypertension and type 2 diabetes in up to 193,933 individuals (55% women) in the FinnGen study. In meta-analyses of up to 567,671 individuals combining FinnGen with the Estonian Biobank and the UK Biobank, we discovered 333 independent loci (P < 5 × 10–9) associated with medication use. Fine-mapping revealed 494 95% credible sets associated with the total number of medication purchases, changes in medication combinations or treatment discontinuation, including 46 credible sets in 40 loci not associated with the underlying treatment targets. The polygenic risk scores (PRS) for cardiometabolic risk factors were strongly associated with the medication-use behavior. A medication-use enhanced multitrait PRS for coronary artery disease matched the performance of a risk factor-based multitrait coronary artery disease PRS in an independent sample (UK Biobank, n = 343,676). In summary, we demonstrate medication-based strategies for identifying cardiometabolic risk loci and provide genome-wide tools for preventing cardiovascular diseases.


  • Open Access

    Genome-wide association study of varicose veins identifies a protective missense variant in GJD3 enriched in the Finnish population

    by Pyry Helkkula, Shabbeer Hassan, Elmo Saarentaus, Emilia Vartiainen, Sanni Ruotsalainen, Jaakko T. Leinonen, Finn Gen, Aarno Palotie, Juha Karjalainen, Mitja Kurki, et al.

    Varicose veins is the most common manifestation of chronic venous disease that displays female-biased incidence. To identify protein-inactivating variants that could guide identification of drug target genes for varicose veins and genetic evidence for the disease prevalence difference between the sexes, we conducted a genome-wide association study of varicose veins in Finns using the FinnGen dataset with 17,027 cases and 190,028 controls. We identified 50 associated genetic loci (P < 5.0 × 10−8) of which 29 were novel including one near ERG with female-specificity (rs2836405-G, OR[95% CI] = 1.09[1.05–1.13], P = 3.1 × 10−8). These also include two X-chromosomal (ARHGAP6 and SRPX) and two autosomal novel loci (TGFB2 and GJD3) with protein-coding lead variants enriched above 56-fold in Finns over non-Finnish non-Estonian Europeans. A low-frequency missense variant in GJD3 (p.Pro59Thr) is exclusively associated with a lower risk for varicose veins (OR = 0.62 [0.55–0.70], P = 1.0 × 10−14) in a phenome-wide scan of the FinnGen data. The absence of observed pleiotropy and its membership of the connexin gene family underlines GJD3 as a potential connexin-modulating therapeutic strategy for varicose veins. Our results provide insights into varicose veins etiopathology and highlight the power of isolated populations, including Finns, to discover genetic variants that inform therapeutic development.


  • Open Access

    Inflammatory and infectious upper respiratory diseases associate with 41 genomic loci and type 2 inflammation

    by Elmo C. Saarentaus, Juha Karjalainen, Joel T. Rämö, Tuomo Kiiskinen, Aki S. Havulinna, Juha Mehtonen, Heidi Hautakangas, Sanni Ruotsalainen, Max Tamlander, Nina Mars, et al.

    Inflammatory and infectious upper respiratory diseases (ICD-10: J30-J39), such as diseases of the sinonasal tract, pharynx and larynx, are growing health problems yet their genomic similarity is not known. We analyze genome-wide association to eight upper respiratory diseases (61,195 cases) among 260,405 FinnGen participants, meta-analyzing diseases in four groups based on an underlying genetic correlation structure. Aiming to understand which genetic loci contribute to susceptibility to upper respiratory diseases in general and its subtypes, we detect 41 independent genome-wide significant loci, distinguishing impact on sinonasal or pharyngeal diseases, or both. Fine-mapping implicated non-synonymous variants in nine genes, including three linked to immune-related diseases. Phenome-wide analysis implicated asthma and atopic dermatitis at sinonasal disease loci, and inflammatory bowel diseases and other immune-mediated disorders at pharyngeal disease loci. Upper respiratory diseases also genetically correlated with autoimmune diseases such as rheumatoid arthritis, autoimmune hypothyroidism, and psoriasis. Finally, we associated separate gene pathways in sinonasal and pharyngeal diseases that both contribute to type 2 immunological reaction. We show shared heritability among upper respiratory diseases that extends to several immune-mediated diseases with diverse mechanisms, such as type 2 high inflammation.


  • Open Access

    Inflammatory and infectious upper respiratory diseases associate with 59 genomic loci that link to type 2 inflammation genes

    by Elmo Saarentaus, Juha Karjalainen, Joel Rämö, Tuomo Kiiskinen, Aki Havulinna, Juha Mehtonen, Heidi Hautakangas, Sanni Ruotsalainen, Sanna Salmi, Matti Pirinen, et al.

    Inflammatory and infectious upper respiratory diseases (IURDs; ICD-10: J30-J39), such as diseases of sinonasal tract, pharynx and larynx, are growing health problems yet their genomic similarity is not known. We analyzed genome-wide association to eight IURDs (61,195 cases) among 260,405 FinnGen participants, meta-analyzing diseases in four groups based on an underlying genetic correlation structure. We aimed to understand which genetic loci contribute to susceptibility to IURDs in general and its subtypes. We detected 59 independent genome-wide significant (GWS) loci, distinguishing impact on sinonasal or pharyngeal diseases, or both. Fine-mapping implicated non-synonymous variants in 16 genes, including 10 linked to immune-related diseases. Phenome-wide analysis implicated asthma and atopic dermatitis at sinonasal disease loci and inflammatory bowel diseases, and other immune-mediated disorders at pharyngeal disease loci. IURDs also genetically correlated with autoimmune diseases such as rheumatoid arthritis, autoimmune hypothyroidism, and psoriasis. Finally, we associated separate gene pathways in sinonasal and pharyngeal diseases that both contribute to type 2 immunological reaction. We show shared heritability among IURDs that extends to several immune-mediated diseases with diverse mechanisms, such as type 2 high inflammation.

  • Open Access

    Polygenic burden has broader impact on health, cognition, and socioeconomic outcomes than most rare and high-risk copy number variants

    by Elmo Christian Saarentaus, Aki Samuli Havulinna, Nina Mars, Ari Ahola-Olli, Tuomo Tapio Johannes Kiiskinen, Juulia Partanen, Sanni Ruotsalainen, Mitja Kurki, Lea Martta Urpa, Lei Chen, et al.

    Copy number variants (CNVs) are associated with syndromic and severe neurological and psychiatric disorders (SNPDs), such as intellectual disability, epilepsy, schizophrenia, and bipolar disorder. Although considered high-impact, CNVs are also observed in the general population. This presents a diagnostic challenge in evaluating their clinical significance. To estimate the phenotypic differences between CNV carriers and non-carriers regarding general health and well-being, we compared the impact of SNPD-associated CNVs on health, cognition, and socioeconomic phenotypes to the impact of three genome-wide polygenic risk score (PRS) in two Finnish cohorts (FINRISK, n = 23,053 and NFBC1966, n = 4895). The focus was on CNV carriers and PRS extremes who do not have an SNPD diagnosis. We identified high-risk CNVs (DECIPHER CNVs, risk gene deletions, or large [>1 Mb] CNVs) in 744 study participants (2.66%), 36 (4.8%) of whom had a diagnosed SNPD. In the remaining 708 unaffected carriers, we observed lower educational attainment (EA; OR = 0.77 [95% CI 0.66–0.89]) and lower household income (OR = 0.77 [0.66–0.89]). Income-associated CNVs also lowered household income (OR = 0.50 [0.38–0.66]), and CNVs with medical consequences lowered subjective health (OR = 0.48 [0.32–0.72]). The impact of PRSs was broader. At the lowest extreme of PRS for EA, we observed lower EA (OR = 0.31 [0.26–0.37]), lower-income (OR = 0.66 [0.57–0.77]), lower subjective health (OR = 0.72 [0.61–0.83]), and increased mortality (Cox’s HR = 1.55 [1.21–1.98]). PRS for intelligence had a similar impact, whereas PRS for schizophrenia did not affect these traits. We conclude that the majority of working-age individuals carrying high-risk CNVs without SNPD diagnosis have a modest impact on morbidity and mortality, as well as the limited impact on income and educational attainment, compared to individuals at the extreme end of common genetic variation. Our findings highlight that the contribution of traditional high-risk variants such as CNVs should be analyzed in a broader genetic context, rather than evaluated in isolation.